Sputnik V Vaccine Elicits Seroconversion and Neutralizing Capacity to SARS CoV-2 after a Single Dose.
Andrés Hugo Rossi,Diego Sebastian Ojeda,Augusto Varese,Lautaro Sanchez,María Mora González López Ledesma,Ignacio Mazzitelli,Anabel Alvarez Juliá,Santiago Oviedo Rouco,Horacio M. Pallarés,Guadalupe S. Costa Navarro,Natali B. Rasetto,Corina I. García,Shirley D. Wenker,Lila Y. Ramis,Magalí G. Bialer,María José de Leone,C. Esteban Hernando,Santiago Sosa,Luciana Bianchimano,Antonella S. Rios,Maria Soledad Treffinger Cienfuegos,Julio J. Caramelo,Yesica Longueira,Yesica Longueira,Natalia Laufer,Natalia Laufer,Diego E. Alvarez,Jorge Carradori,Dariana Pedrozza,Alejandra Rima,Cecilia Echegoyen,Regina Ercole,Paula Gelpi,Susana Marchetti,Martin Zubieta,Guillermo Horacio Docena,Nicolás Kreplak,Marcelo J. Yanovsky,Jorge Geffner,Marina Pifano,Andrea V. Gamarnik +40 more
- Vol. 2, Iss: 8, pp 100359-100359
TLDR
In this article, the authors evaluated SARS-CoV-2-specific antibody responses after Sputnik V vaccination of healthcare workers in Argentina, measuring IgG anti-spike titers and neutralizing capacity after one and two doses in a cohort of naive or previously infected volunteers.Abstract:
Massive vaccination offers great promise for halting the global COVID-19 pandemic. However, limited supply and uneven vaccine distribution create an urgent need to optimize vaccination strategies. We evaluate SARS-CoV-2-specific antibody responses after Sputnik V vaccination of healthcare workers in Argentina, measuring IgG anti-spike titers and neutralizing capacity after one and two doses in a cohort of naive or previously infected volunteers. By 21 days after receiving the first dose of vaccine, 94% of naive participants develop spike-specific IgG antibodies. A single Sputnik V dose elicits higher antibody levels and virus neutralizing capacity in previously infected individuals than in naive ones receiving the full two-dose schedule. The high seroconversion rate after a single dose in naive participants suggests a benefit of delaying second dose administration to increase the number of people vaccinated. The data presented provide information for guiding public health decisions in light of the current global health emergency.read more
Citations
More filters
An open, non-randomised, phase 1/2 trial on the safety, tolerability, and immunogenicity of single-dose vaccine “Sputnik Light” for prevention of coronavirus infection in healthy adults
A. I. Tukhvatulin,Inna V. Dolzhikova,Dmitry V. Shcheblyakov,Olga V. Zubkova,Alina S. Dzharullaeva,Anna V. Kovyrshina,Nadezhda L. Lubenets,Daria M. Grousova,Alina S. Erokhova,Andrei G. Botikov,Fatima M. Izhaeva,Olga Popova,T A Ozharovskaia,Ilias B Esmagambetov,Irina A Favorskaya,Denis I. Zrelkin,Daria V Voronina,Dmitry N. Shcherbinin,Alexander S. Semikhin,Yana V. Simakova,Elizaveta A. Tokarskaya,M M Shmarov,Natalia A. Nikitenko,Vladimir A. Gushchin,Elena A Smolyarchuk,Tatiana G. Zubkova,Konstantin A. Zakharov,Vasiliy B. Vasilyuk,Sergei V. Borisevich,B.S. Naroditsky,Denis Y. Logunov,Alexander L. Gintsburg +31 more
TL;DR: In this paper, a single-dose vaccine based on recombinant adenovirus type 26 (rAd26) vector carrying the gene for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike (S) glycoprotein -Sputnik Light was developed.
Journal ArticleDOI
Controversy surrounding the Sputnik V vaccine.
TL;DR: The Sputnik V COVID-19 vaccine is a member of the so-called vector vaccines and uses two different vectors (Ad26 priming and Ad5 boost) to reduce the risk of a reduction in the effectiveness of the vaccination.
Journal ArticleDOI
Long-term analysis of antibodies elicited by SPUTNIK V: A prospective cohort study in Tucumán, Argentina.
TL;DR: In this paper , the authors studied the long-term humoral immune response in naïve and previously infected volunteers who received Gam-COVID-Vac (SPUTNIK V) for 602 healthcare workers at 0, 14, 28, 60 and 180 days after receiving the vaccine.
Long-term analysis of antibodies elicited by SPUTNIK V: A prospective cohort study in Tucumán, Argentina.
Rossana Elena Chahla,Rodrigo Hernán Tomas-Grau,Silvia Ines Cazorla,Diego Ploper,Esteban Vera Pingitore,Mónica Aguilar López,Patricia Aznar,María Elena Alcorta,Eva Maria del Mar Velez,Agustin Stagnetto,César Ávila,Carolina Maldonado-Galdeano,Sergio B. Socías,Dar Heinze,Silvia Adriana Navarro,Conrado Juan Llapur,Dardo Costa,Isolina Flores,Alexis Edelstein,Shreyas Kowdle,Claudia Perandones,Benhur Lee,Gabriela Apfelbaum,Raul Mostoslavsky,Gustavo Mostoslavsky,Gabriela Perdigón,Rosana Chehín +26 more
TL;DR: In this article, the long-term humoral immune response in naive and previously infected volunteers who received Gam-COVID-Vac (SPUTNIK V) was studied.
Journal ArticleDOI
Humoral response to the BBIBP-CorV vaccine over time in healthcare workers with or without exposure to SARS-CoV-2
TL;DR: In this article , SARS-CoV-2-specific humoral response was analyzed over time in a group of healthcare workers who underwent vaccination with BBIBP-CorV (Sinopharm) vaccine in Argentina.
References
More filters
Journal ArticleDOI
Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia.
Denis Y. Logunov,Inna V. Dolzhikova,Dmitry V. Shcheblyakov,A. I. Tukhvatulin,Olga V. Zubkova,Alina S. Dzharullaeva,Anna V. Kovyrshina,Nadezhda L. Lubenets,Daria M. Grousova,Alina S. Erokhova,Andrei G. Botikov,Fatima M. Izhaeva,Olga Popova,Tatiana A Ozharovskaya,Ilias B Esmagambetov,Irina A Favorskaya,Denis I. Zrelkin,Daria V Voronina,Dmitry N. Shcherbinin,Alexander S. Semikhin,Yana V. Simakova,Elizaveta A. Tokarskaya,Daria A. Egorova,M M Shmarov,Natalia A. Nikitenko,Vladimir A. Gushchin,Elena A Smolyarchuk,Sergey Zyryanov,Sergei V. Borisevich,Boris S. Naroditsky,Alexander L. Gintsburg +30 more
TL;DR: Gam-COVID-Vac (Sputnik V) showed a good safety profile and induced strong humoral and cellular immune responses in participants in phase 1/2 clinical trials as discussed by the authors.
Journal ArticleDOI
Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia.
Denis Y. Logunov,Inna V. Dolzhikova,Olga V. Zubkova,Amir I Tukhvatullin,Dmitry V. Shcheblyakov,Alina S. Dzharullaeva,Daria M. Grousova,Alina S. Erokhova,Anna V. Kovyrshina,Andrei G. Botikov,Fatima M. Izhaeva,Olga Popova,Tatiana A Ozharovskaya,Ilias B Esmagambetov,Irina A Favorskaya,Denis I. Zrelkin,Daria V Voronina,Dmitry N. Shcherbinin,Alexander S. Semikhin,Yana V. Simakova,Elizaveta A. Tokarskaya,Nadezhda L. Lubenets,Daria A. Egorova,M M Shmarov,Natalia A. Nikitenko,Morozova Lf,Elena A Smolyarchuk,Evgeny V Kryukov,Vladimir F Babira,Sergei V. Borisevich,Boris S. Naroditsky,Alexander L. Gintsburg +31 more
TL;DR: The heterologous rAd26 and rAd5 vector-based COVID-19 vaccine has a good safety profile and induced strong humoral and cellular immune responses in participants and was safe and well tolerated.
Journal ArticleDOI
Antibody Responses in Seropositive Persons after a Single Dose of SARS-CoV-2 mRNA Vaccine.
Florian Krammer,Komal Srivastava,Hala Alshammary,Angela Amoako,Mahmoud Awawda,Katherine Beach,Maria Bermudez-Gonzalez,Dominika A. Bielak,Juan Manuel Carreño,Rachel Chernet,Lily Q. Eaker,Emily D. Ferreri,Daniel L. Floda,Charles R Gleason,Joshua Hamburger,Kaijun Jiang,Giulio Kleiner,Denise Jurczyszak,Julia C. Matthews,Wanni A. Mendez,Ismail Nabeel,Lubbertus C. F. Mulder,Ariel Raskin,Kayla T. Russo,Ashley Beathrese T. Salimbangon,Miti Saksena,Amber S. Shin,Gagandeep Singh,Levy A. Sominsky,Daniel Stadlbauer,Ania Wajnberg,Viviana Simon +31 more
TL;DR: In this article, the responses of seropositive persons to a single SARS-CoV-2 vaccine were surveyed and they reported that they had antibodies to the spike protein of SARS CoV2.
Journal ArticleDOI
Antibody responses to the BNT162b2 mRNA vaccine in individuals previously infected with SARS-CoV-2.
Joseph E. Ebinger,Justyna Fert-Bober,Ignat Printsev,Min Wu,Nancy Sun,John Prostko,Edwin C. Frias,James L. Stewart,Jennifer E. Van Eyk,Jonathan Braun,Susan Cheng,Kimia Sobhani +11 more
TL;DR: In this paper, the authors observed that spike-specific IgG antibody levels and ACE2 antibody binding inhibition responses elicited by a single vaccine dose in individuals with prior SARS-CoV-2 infection were similar to those seen after two doses of vaccine in individuals without prior infection.
Journal ArticleDOI
Neutralizing Antibody and Soluble ACE2 Inhibition of a Replication-Competent VSV-SARS-CoV-2 and a Clinical Isolate of SARS-CoV-2
James Brett Case,Paul W. Rothlauf,Paul W. Rothlauf,Rita E. Chen,Zhuoming Liu,Haiyan Zhao,Arthur S. Kim,Louis Marie Bloyet,Qiru Zeng,Stephen Tahan,Lindsay Droit,Ma. Xenia G. Ilagan,Michael A Tartell,Michael A Tartell,Gaya K. Amarasinghe,Jeffrey P. Henderson,Shane Miersch,Mart Ustav,Sachdev S. Sidhu,Herbert W. Virgin,David Wang,Siyuan Ding,Davide Corti,Elitza S. Theel,Daved H. Fremont,Michael S. Diamond,Sean P. J. Whelan +26 more
TL;DR: Two neutralizing activities of various antibodies and ACE2-Fc soluble decoy protein in both assays revealed a high degree of concordance, which will help define correlates of protection for antibody-based countermeasures and vaccines against SARS-CoV-2.
Related Papers (5)
Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia.
Denis Y. Logunov,Inna V. Dolzhikova,Dmitry V. Shcheblyakov,A. I. Tukhvatulin,Olga V. Zubkova,Alina S. Dzharullaeva,Anna V. Kovyrshina,Nadezhda L. Lubenets,Daria M. Grousova,Alina S. Erokhova,Andrei G. Botikov,Fatima M. Izhaeva,Olga Popova,Tatiana A Ozharovskaya,Ilias B Esmagambetov,Irina A Favorskaya,Denis I. Zrelkin,Daria V Voronina,Dmitry N. Shcherbinin,Alexander S. Semikhin,Yana V. Simakova,Elizaveta A. Tokarskaya,Daria A. Egorova,M M Shmarov,Natalia A. Nikitenko,Vladimir A. Gushchin,Elena A Smolyarchuk,Sergey Zyryanov,Sergei V. Borisevich,Boris S. Naroditsky,Alexander L. Gintsburg +30 more
Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia.
Denis Y. Logunov,Inna V. Dolzhikova,Olga V. Zubkova,Amir I Tukhvatullin,Dmitry V. Shcheblyakov,Alina S. Dzharullaeva,Daria M. Grousova,Alina S. Erokhova,Anna V. Kovyrshina,Andrei G. Botikov,Fatima M. Izhaeva,Olga Popova,Tatiana A Ozharovskaya,Ilias B Esmagambetov,Irina A Favorskaya,Denis I. Zrelkin,Daria V Voronina,Dmitry N. Shcherbinin,Alexander S. Semikhin,Yana V. Simakova,Elizaveta A. Tokarskaya,Nadezhda L. Lubenets,Daria A. Egorova,M M Shmarov,Natalia A. Nikitenko,Morozova Lf,Elena A Smolyarchuk,Evgeny V Kryukov,Vladimir F Babira,Sergei V. Borisevich,Boris S. Naroditsky,Alexander L. Gintsburg +31 more
Neutralizing Activity of Sera from Sputnik V-Vaccinated People against Variants of Concern (VOC: B.1.1.7, B.1.351, P.1, B.1.617.2, B.1.617.3) and Moscow Endemic SARS-CoV-2 Variants.
Vladimir A. Gushchin,Inna V. Dolzhikova,Shchetinin Am,Alina S. Odintsova,Andrei E. Siniavin,Maria A. Nikiforova,Andrei A. Pochtovyi,Elena V. Shidlovskaya,Nadezhda A. Kuznetsova,Olga A. Burgasova,Liudmila V. Kolobukhina,Anna A. Iliukhina,Anna V. Kovyrshina,Botikov Ag,Aleksandra V. Kuzina,Daria M. Grousova,A. I. Tukhvatulin,Dmitry V. Shcheblyakov,Olga V. Zubkova,Oksana V. Karpova,Olga L. Voronina,Natalia N. Ryzhova,Ekaterina I. Aksenova,M.S. Kunda,Dmitry Lioznov,Daria Danilenko,Andrey Komissarov,Artem P. Tkachuck,Denis Y. Logunov,Alexander L. Gintsburg +29 more
Single-dose SARS-CoV-2 vaccine in a prospective cohort of COVID-19 patients
Marit J. van Gils,Hugo D.G. Willegen,Elke Wynberg,Alvin X. Han,Karlijn van der Straten,Anouk Verveen,Romy Lebbink,Maartje Dijkstra,Judith A. Burger,Melissa Oomen,Kadija Tejjani,Joey H. Bouhuijs,Brent Appelman,A.H. Ayesha Lavell,Meliawatti Poniman,Tom G. Caniels,Ilja Bontjer,Lonneke A. van Vught,Alexander P.J. Vlaar,Jonne J. Sikkens,Marije K. Bomers,Rogier W. Sanders,Rogier W. Sanders,Neeltje A. Kootstra,Colin A. Russell,Maria Prins,Godelieve J. de Bree,Menno D. de Jong +27 more